Newsfeeds - Spark Newswire

1 minute read

Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program

Today, 5:47 AM

Akero Therapeutics Inc (NASDAQ:AKRO) completed enrollment of the Phase 2b SYMMETRY main study evaluating efruxifermin (EFX) for non-alcoholic steatohepatitis (NASH) in…

AKRO

1 minute read

Akero Therapeutics Completes Enrollment Of Phase 2b SYMMETRY Study And Announces Expected 2023 Milestones

By Benzinga Newsdesk

Today, 5:47 AM

Results of the main study in patients with compensated cirrhosis due to NASH (F4) expected in fourth quarter of 2023 Results of the cohort D expansion to evaluate EFX in combination with GLP-1 therapy in patients with

AKRO

5 minute read

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 5:47 AM

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

ACLX

6 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 5:47 AM

On Friday, 68 companies reached new 52-week highs.

ABC

1 minute read

Morgan Stanley Maintains Equal-Weight on Akero Therapeutics, Raises Price Target to $40

By Benzinga Newsdesk

Today, 5:47 AM

Morgan Stanley analyst Matthew Harrison maintains Akero Therapeutics (NASDAQ:AKRO) with a Equal-Weight and raises the price target from $30 to $40.

AKRO

6 minute read

Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday

By Lisa Levin

Today, 5:47 AM

Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.

AAN

4 minute read

Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

Today, 5:47 AM

Gainers

AEHL

1 minute read

Thanks To Encouraging Data, These Mid-Cap Stocks Layout $300M Equity Raise

By Vandana Singh

Today, 5:47 AM

POINT Biopharma Global Inc (NASDAQ:PNT) priced its public offering of 13.9 million shares at $9.00 per share, with gross proceeds…

AKRO

12 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 14, 2022

By Benzinga Insights

Today, 5:47 AM

Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low of $2.89. Moreover, at the end of the last trading period, the closing price was at $4.26.

AGL

1 minute read

Morgan Stanley Maintains Equal-Weight on Akero Therapeutics, Raises Price Target to $30

By Benzinga Newsdesk

Today, 5:47 AM

Morgan Stanley analyst Matthew Harrison maintains Akero Therapeutics (NASDAQ:AKRO) with a Equal-Weight and raises the price target from $26 to $30.

AKRO